Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms

Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 1054, 10.1016/S0140-6736(05)74230-6 Moulard, 2014, Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union, Eur J Haematol, 92, 289, 10.1111/ejh.12256 Tefferi, 2007, Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2 V617F, Semin Thromb Hemost, 1, 313, 10.1055/s-2007-976165 Vannucchi, 2007, Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, 110, 840, 10.1182/blood-2006-12-064287 Kaifie, 2016, Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J Hematol Oncol, 9, 18, 10.1186/s13045-016-0242-9 Marchioli, 2005, Vascular and neoplastic risk in a large cohort of patients with polycythemia vera, J Clin Oncol, 23, 2224, 10.1200/JCO.2005.07.062 Campbell, 2005, Management of polycythemia vera and essential thrombocythemia, Hematology, 2005, 201, 10.1182/asheducation-2005.1.201 Carobbio, 2007, Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status, Blood, 109, 2310, 10.1182/blood-2006-09-046342 Passamonti, 2010, A prospective study of 338 patients with polycythemia vera: the impact of JAK2(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, 24, 1574, 10.1038/leu.2010.148 Cascavilla, 2015, Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study, Drug Des Devel Ther, 9, 2687 Alvarez-Larrán, 2014, JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events, Am J Hematol, 89, 517, 10.1002/ajh.23676 Borowczyk, 2015, The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms, Thromb Res, 135, 272, 10.1016/j.thromres.2014.11.006 Malysz, 2009, Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm, Ann Clin Lab Sci, 39, 345 Schwarz, 2016, Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide, Eur J Haematol, 96, 98, 10.1111/ejh.12554 De Stefano, 2009, Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia, Haematologica, 94, 733, 10.3324/haematol.13869 Trifa, 2014, The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia, Ann Hematol, 93, 203, 10.1007/s00277-013-1838-6 Miller, 1988, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res, 16, 1215, 10.1093/nar/16.3.1215 Larsen, 2007, The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders, Br J Haematol, 136, 745, 10.1111/j.1365-2141.2007.06497.x Zoller, 1994, Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C, J Clin Invest, 94, 2521, 10.1172/JCI117623 Poort, 1996, A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, 88, 3698, 10.1182/blood.V88.10.3698.bloodjournal88103698 Passamonti, 2018, Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia, Am J Med, 117, 755, 10.1016/j.amjmed.2004.06.032 Barosi, 2012, Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis, PLoS One, 7, e35631, 10.1371/journal.pone.0035631 Finazzi, 2007, Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status, Haematologica, 92, 135, 10.3324/haematol.10634 1995, Polycythemia vera: the natural history of 1213 patients followed for 20 years, Ann Intern Med, 123, 656, 10.7326/0003-4819-123-9-199511010-00003 Barbui, 2010, Thrombosis in primary myelofibrosis: incidence and risk factors, Blood, 115, 778, 10.1182/blood-2009-08-238956 Buxhofer-Ausch, 2012, Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients, Am J Hematol, 87, 669, 10.1002/ajh.23217 Stein, 2010, Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders, Haematologica, 95, 1090, 10.3324/haematol.2009.014407 Lekovic, 2014, The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia, Med Oncol, 31, 231, 10.1007/s12032-014-0231-1 Landolfi, 2007, Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera, Blood, 109, 2446, 10.1182/blood-2006-08-042515 Gangat, 2011, DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status, J Clin Oncol, 29, 392, 10.1200/JCO.2010.32.2446 Benites, 2013, Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome, Clinics, 68, 339, 10.6061/clinics/2013(03)OA09 Gisslinger, 2005, Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study, Haematologica, 90, 408 Coen, 2001, Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism, Croat Med J, 42, 488 Afshar-Kharghan, 2006, Leukocyte adhesion and thrombosis, Curr Opin Hematol, 13, 34, 10.1097/01.moh.0000190107.54790.de Carobbio, 2011, Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients, Blood, 117, 5857, 10.1182/blood-2011-02-339002 Wilkerson, 2002, Aging and thrombosis, Semin Thromb Hemost, 28, 555, 10.1055/s-2002-36700 Barbui, 2015, CME article development and validation of an International Prognostic Score of Thrombosis in World Health Organization—Essential Thrombocythemia (IPSET-Thrombosis ), Blood, 120, 5128, 10.1182/blood-2012-07-444067 Vannucchi, 2007, Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden, Leukemia, 21, 1952, 10.1038/sj.leu.2404854 Antonioli, 2008, Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, Haematologica, 93, 41, 10.3324/haematol.11653 Guglielmelli, 2009, Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2 V617F mutated allele, Hematology, 114, 1477